Walden Group Healthcare M&A Blog

Emergent BioSolutions Is Buying PaxVax For $270m

08/10/2018
Emergent BioSolutions, Inc., a $560.8m specialty pharmaceutical company focused on public health threats, is buying PaxVax, Inc., a PE- backed company focuses on specialty vaccines against existing and emerging infectious diseases. The deal expands Emergent's specialty vaccine platform. PaxVax's main product include Vivotif, the only oral...
Read More
The Impact of Trump’s Tariffs

08/07/2018
President Trump’s tariffs on Chinese imports could cost American medical device makers more than $1.5b annually, according to some estimates. MRIs, CT scanners, pacemakers, sonograms and other imaging components were all included in the list of items subject to the 25% tariffs that went into effect on June 6. Also included are a variety of...
Read More
Celgene Acquires Juno Therapeutics For $9b

07/18/2018
Celgene Corp., a $12.5b developer of therapies for cancer and inflammatory diseases is buying Juno Therapeutics Inc., a Seattle-based biotech company making cutting-edge cancer immunotherapy treatments. The Deal expands Celgene’s portfolio of blood-cancer drugs. Juno is one of leaders in a new kind of cancer treatment, known as CAR-T, that...
Read More
Sweeping New EU Regulations, Taking Effect in 2020, Will Create Upheavals in The European Medtech and IVD Markets

07/11/2018
Starting in 2020 medtech firms will be competing in a significantly more complicated European market. New Medical Devices Regulations (MDR) were written to strengthen device safety standards but they will make it far more onerous and expensive for medtech firms to market their products in Europe. Because of the MDR, many smaller companies may...
Read More
Novartis, Abbott, GE, Siemens, and Other Healthcare Giants Are Reversing Previous Diversification Strategies

07/11/2018
Novartis/Alcon After assessing strategic options for Alcon, Novartis is spin-ning it out to shareholders. As a result, both companies will now rivet on their core strengths –pharmaceuticals and oph-thalmic devices, respectively. When Novartis acquired Alcon in 2011 for $52b, the business included surgical, vision care and ophthalmic...
Read More